You are here

Alpha Cognition Inc.

Alpha Cognition Inc.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
ACOG
CSE Index: 
Currency: 

Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS.  ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.  

You are here

Alpha Cognition Inc. (ACOG)

SEDAR Information

Company Info

Address
c/o 1200 - 750 West Pender Street
Vancouver, BC V6C 2T8
Canada
Phone
(858) 344-4375
Email
[email protected]
Website
https://www.alphacognition.com
Listing date
Monday, May 1, 2023
Transfer Agent
Computershare Investor Services Inc.

Capitalization

Issued & Outstanding: 
15531282
Reserved for Issuance: 
4900617

Company Officers

Michael McFadden, Chief Executive Officer
Ken Cawkell, Corporate Secretary
Lauren D'Angelo, Chief Operating Officer
Len Mertz, Chairman
Henry Du, Interim CFO

Bulletins

01/11/2024

2024-1103 – Consolidation - Alpha Cognition Inc. (ACOG)

le 1 novembre/November 2024

Alpha Cognition Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty five (25) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 6,034,221 common shares.

The name and symbol will not change.